Development and characterization of a synthetic promoter for selective expression in proliferating endothelial cells

Journal of Gene Medicine

Volumn 8, Issue 4, 2006, Pages 514-523

  Szymanski, P ^a   Anwer, K ^b   Sullivan, S M ^c,d  

^a BAYER AG   (Germany)

^b Expression Genetics Inc   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

^d NONE   (United States)

Author keywords

Cdc6; Endothelial cells; Endothelin; Gene therapy; Tissue specific promoter

Indexed keywords

CELL CYCLE PROTEIN 6; CYCLIN A; ENDOTHELIN; ESTRADIOL; LIPOPLEX; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL CYCLE; CELL DIVISION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENDOTHELIUM CELL; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; NUCLEOTIDE SEQUENCE; OVARIECTOMY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SUBCUTANEOUS TISSUE TUMOR; UTERUS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CATTLE; CELL CYCLE PROTEINS; CELL LINE; CELL PROLIFERATION; ENDOTHELIAL CELLS; ENDOTHELINS; ENHANCER ELEMENTS (GENETICS); FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; NIH 3T3 CELLS; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); TRANSFECTION; TRANSPLANTS;

ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 33646259237     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.875     Document Type: Article

References (50)

1. Curiel DT, Douglas JT. In Contemporary Cancer Research, vol. 1, Nickoloff JA (ed). Humana Press: Totowa, NJ, 2005; 472.
2. El-Aneed A. Current strategies in cancer gene therapy. Eur J Pharmacol 2004; 498: 1-8.
3. Lopez CA, Park JO, Mauceri HJ, et al. Control of gene therapy by MDR1 and EGR1 promoter sequences in transcriptional targeting by chemotherapy (Review). Int J Oncol 2004; 24: 731-736.
4. Kursa M, Walker GF, Roessler V, et al. Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer. Bioconjugate Chem 2003; 14: 222-231.
5. Perabo L, Buning H, Kofler DM, et al. In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther 2003; 8: 151-157.
6. De Palma M, Venneri MA, Naldini L. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther 2003; 14: 1193-1206.
7. Buning H, Ried MU, Perabo L, et al. Receptor targeting of adeno-associated virus vectors. Gene Ther 2003; 10: 1142-1151.
8. Anwer K, Bailey A, Sullivan SM. Targeted gene delivery: a two-pronged approach. Crit Rev Ther Drug Carrier Syst 2000; 17: 377-424.
9. Kaliberov SA, Buchsbaum DJ, Gillespie GY, et al. Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells. Mol Ther 2002; 6: 190-198.
10. Koshikawa N, Takenaga K, Tagawa M, et al. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res 2000; 60: 2936-2941.
11. Kaliberov SA, Kaliberova LN, Stockard CR, et al. Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer. Mol Ther 2004; 10: 1059-1070.
12. St. George JA. Gene therapy progress and prospects: adenoviral vectors. Gene Ther 2003; 10: 1135-1141.
13. Henglein B, Chenivesse X, Wang J, et al. Structure and cell cycle-regulated transcription of the human cyclin A gene. Proc Natl Acad Sci U S A 1994; 91: 5490-5494.
14. Piaggio G, Farina A, Perrotti D, et al. Structure and growth-dependent regulation of the human cyclin B1 promoter. Exp Cell Res 1995; 216: 396-402.
15. Farina A, Gaetano C, Crescenzi M, et al. The inhibition of cyclin B1 gene transcription in quiescent NIH3T3 cells is mediated by an E-box. Oncogene 1996; 13: 1287-1296.
16. Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 1994; 8: 1514-1525.
17. Ohtani K, DeGregori J, Leone G, et al. Expression of the HsOrc1 gene, a human ORC1 homolog, is regulated by cell proliferation via the E2F transcription factor. Mol Cell Biol 1996; 16: 6977-6984.
18. Williams RS, Shohet RV, Stillman B. A human protein related to yeast Cdc6p. Proc Natl Acad Sci U S A 1997; 94: 142-147.
19. Yan Z, DeGregori J, Shohet R, et al. Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proc Natl Acad Sci USA 1998; 95: 3603-3608.
20. Bu X, Quertermous T. Identification of an endothelial cell-specific regulatory region in the murine endothelin-1 gene. J Biol Chem 1997; 272: 32 613 -32 622.
21. Anwer K, Shi M, Frenceh MF, et al. Systemic effect of human growth hormone after intramuscular injection of a single dose of a muscle specific gene medicine. Hum Gene Ther 1998; 9: 650-670.
22. O'Malley BW Jr, Cope KA, Johnson CS, et al. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 1997; 123: 20-24.
23. Blezinger P, Wang J, Gondo M, et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol 1999; 17: 343-348.
24. Fadel BM, Boutet SC, Quertermous T. Endothelial cell-specific regulation of the murine endothelin-1 gene. J Cardiovasc Pharmacol 2000; 35: S7-11.
25. Tibbetts TA, Mendoza-Meneses M, O'Malley BW, et al. Mutual and intercompartmental regulation of estrogen receptor and progesterone receptor expression in the mouse uterus. Biol Reprod 1998; 59: 1143-1152.
26. Anwer K, Kao G, Proctor B, et al. Optimization of cationic lipid/DNA complexes for systemic gene transfer to tumor lesions. J Drug Target 2000; 8: 125-135.
27. Anwer K, Meaney C, Kao G, et al. Cationic lipid-based delivery system for systemic cancer gene therapy. Cancer Gene Ther 2000; 7: 1156-1164.
28. Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 1995; 6: 881-893.
29. Koch PE, Guo ZS, Kagawa S, et al. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. Mol Ther 2001; 3: 278-283.
30. Bui LA, Butterfield LH, Kim JY, et al. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum Gene Ther 1997; 8: 2173-2182.
31. Murayama Y, Tadakuma T, Kunitomi M, et al. Cell-specific expression of the diphtheria toxin A-chain coding sequence under the control of the upstream region of the human alpha-fetoprotein gene. J Surg Oncol 1999; 70: 145-149.
32. Kanai F, Lan KH, Shiratori Y, et al. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res 1997; 57: 461 -465.
33. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
34. Wirth T, Kuhnel F, Fleischmann-Mundt B, et al. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Cancer Res 2005; 65: 7393-7402.
35. Wirth T, Kuhnel F, Kubicka S. Telomerase-dependent gene therapy. Curr Mol Med 2005; 5: 243-251.
36. Heidenreich R, Kappel A, Breier G. Tumor endothelium-specific transgene expression directed by vascular endothelial growth factor receptor-2 (Flk-1) promoter/enhancer sequences. Cancer Res 2000; 60: 6142-6147.
37. Shichinohe T, Bochner BH, Mizutani K, et al. Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Ther 2001; 8: 879-889.
38. Greenberger S, Shaish A, Varda-Bloom N, et al. Transcription-controlled gene therapy against tumor angiogenesis. J Clin Invest 2004; 113: 1017-1024.
39. Hofland HE, Nagy D, Liu JJ, et al. In vivo gene transfer by intravenous administration of stable cationic lipid/DNA complex. Pharm Res 1997; 14: 742-749.
40. Lee ME, Bloch KD, Clifford JA, et al. Functional analysis of the endothelin-1 gene promoter. Evidence for an endothelial cell-specific cis-acting sequence. J Biol Chem 1990; 265: 10 446-10 450.
41. Lee ME, de la Monte SM, Ng SC, et al. Expression of the potent vasoconstrictor endothelin in the human central nervous system. J Clin Invest 1990; 86: 141-147.
42. Guo D, Jia Q, Song HY, et al. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 1995; 270: 6729-6733.
43. Ronicke V, Risau W, Breier G. Characterization of the endothelium-specific murine vascular endothelial growth factor receptor-2 (Flk-1) promoter. Circ Res 1996; 79: 277-285.
44. Cowan PJ, Shinkel TA, Witort EJ, et al. Targeting gene expression to endothelial cells in transgenic mice using the human intercellular adhesion molecule 2 promoter. Transplantation 1996; 62: 155-160.
45. Hsiao KM, McMahon SL, Farnham PJ. Multiple DNA elements are required for the growth regulation of the mouse E2F1 promoter. Genes Dev 1994; 8: 1526-1537.
46. Schulze A, Zerfass K, Spitkovsky D, et al. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc Natl Acad Sci U S A 1995; 92: 11264-11268.
47. Zwicker J, Gross C, Lucibello FC, et al. Cell cycle regulation of Cdc25C transcription is mediated by the periodic repression of the glutamine-rich activators NF-Y and Sp1. Nucleic Acids Res 1995; 23: 3822-3830.
48. Diffley JF, Labib K. The chromosome replication cycle. J Cell Sci 2002; 115: 869-872.
49. Hateboer G, Wobst A, Petersen BO, et al. Cell cycle-regulated expression of mammalian Cdc6 is dependent on E2F. Mol Cell Biol 1998; 18: 6679-6697.
50. Ohtani K, Tsujimoto A, Ikeda M, et al. Regulation of cell growth-dependent expression of mammalian Cdc6 gene by the cell cycle transcription factor E2F. Oncogene 1998; 17: 1777-1785.